Evidence mapPaperPMID 32414745Full record

SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2020

BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?

Robert A Lewis, Charlotte Durrington, Robin Condliffe, David G Kiely

Open access · diamondAbstract readSystematic Review
In one paragraph

Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 2 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Pooled it
  3. Trial
  4. Observational
  5. Article
  6. Article
  7. Journal of preventive medicine and hygiene · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Evaluation and Management of Sepsis in Pulmonary Hypertension.Journal of intensive care medicine · 2025
    Review
  18. Review
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Robert A LewisSheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
Charlotte DurringtonSheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
Robin CondliffeSheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
David G KielySheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK david.kiely1@nhs.net.ORCID https://orcid.org/0000-0003-0184-6502
Royal Hallamshire Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the advent of new therapies and improved outcomes in patients with pulmonary arterial hypertension (PAH), it remains a life-shortening disease and the time to diagnosis remains unchanged. Strategies to improve outcomes are therefore currently focused on earlier diagnosis and a treatment approach aimed at moving patients with PAH into a category of low-risk of 1-year mortality. B-type natriuretic peptide (BNP; or brain natriuretic peptide) and N-terminal prohormone of BNP (NT-proBNP) are released from cardiac myocytes in response to mechanical load and wall stress. Elevated levels of BNP and NT-proBNP are incorporated into several PAH risk stratification tools and screening algorithms to aid diagnosis of systemic sclerosis. We have undertaken a systematic review of the literature with respect to the use of BNP and NT-proBNP in PAH and the use of these biomarkers in the diagnosis and risk stratification of PAH, their relation to pulmonary haemodynamics and the potential for point-of-care testing to improve diagnosis and prognosis.

Indexed as

Arterial PressurePoint-of-Care SystemsPoint-of-Care TestingAnimalsBiomarkersEarly DiagnosisHumansNatriuretic Peptide, BrainPeptide FragmentsPredictive Value of TestsPrognosisPulmonary Arterial HypertensionPulmonary ArteryReproducibility of ResultsRisk AssessmentRisk FactorsBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Identifiers

PMID32414745
PMCPMC9488846
OpenAlexW3025529204

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.